T. Rowe Price Investment Management, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,872,904 shares of ALNY stock, worth $426 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
2,872,904
Previous 3,426,063
16.15%
Holding current value
$426 Million
Previous $656 Million
34.53%
% of portfolio
0.26%
Previous 0.43%
Shares
7 transactions
Others Institutions Holding ALNY
# of Institutions
584Shares Held
104MCall Options Held
2.82MPut Options Held
1.75M-
Capital World Investors Los Angeles, CA12.8MShares$1.9 Billion0.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$1.78 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY9.03MShares$1.34 Billion0.03% of portfolio
-
Wellington Management Group LLP Boston, MA7.21MShares$1.07 Billion0.2% of portfolio
-
Baillie Gifford & CO6.62MShares$983 Million0.78% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $18.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...